StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research report sent to investors on Monday. The firm issued a sell rating on the stock.

Separately, Cantor Fitzgerald reaffirmed an overweight rating and set a $2.50 target price on shares of VolitionRx in a research report on Thursday, May 16th.

VolitionRx Price Performance

NYSE:VNRX opened at $0.72 on Monday. VolitionRx has a twelve month low of $0.55 and a twelve month high of $1.79. The company has a fifty day moving average of $0.77 and a 200-day moving average of $0.85. The firm has a market capitalization of $59.93 million, a P/E ratio of -1.57 and a beta of 1.26.

VolitionRx (NYSE:VNRX) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.27 million. On average, analysts anticipate that VolitionRx will post -0.34 EPS for the current fiscal year.

Institutional Trading of VolitionRx

A hedge fund recently bought a new stake in VolitionRx stock. Silverberg Bernstein Capital Management LLC purchased a new position in shares of VolitionRx Limited (NYSE:VNRX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned about 0.19% of VolitionRx as of its most recent filing with the Securities and Exchange Commission (SEC). 8.09% of the stock is owned by institutional investors and hedge funds.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.